Business context and reporting period
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing oral extended-release nalbuphine (nalbuphine ER). This Form 10-K reports the fiscal year ended December 31, 2019; it is an annual report, not a standalone quarterly report. The company had no approved products or product-sale revenue.
Its lead program is the PRISM Phase 2b/3 trial for severe pruritus associated with prurigo nodularis. Other programs include a Phase 2 trial for chronic cough in idiopathic pulmonary fibrosis (IPF), a Phase 1b hepatic-impairment study, and planned Phase 2 programs for pruritus associated with primary biliary cholangitis (PBC) and levodopa-induced dyskinesia (LID).
Key financial metrics
| Metric | 2019 | 2018 |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $19.3 million | $14.1 million |
| General and administrative expense | $7.3 million | $4.3 million |
| Total operating expenses | $26.6 million | $18.4 million |
| Net loss | $26.1 million | $20.5 million |
| Net cash used in operating activities | $23.1 million | $18.3 million |
| Cash and cash equivalents at year-end | $57.3 million | $7.2 million |
| Total assets | $60.0 million | $10.5 million |
| Debt outstanding | None | None |
Profit margins are not meaningful because the company had no revenue and incurred operating losses. Current assets were $59.6 million and current liabilities were $5.2 million at December 31, 2019. Management estimated that cash would fund operations into the third quarter of 2021, subject to assumptions; the financial-statement note states funding through at least 12 months from the March 16, 2020 issuance date. The company says additional funding will be needed.
Material changes versus the prior comparable period
- Net loss increased by $5.5 million year over year. R&D expense rose 37%, primarily because of greater clinical-trial activity; G&A increased 69%, including public-company and stock-based compensation costs.
- Operating cash use increased by $4.8 million. Cash rose substantially after the May 2019 IPO and concurrent private placement, which generated combined net proceeds of approximately $62.1 million. The company reported that IPO proceeds remained invested in money-market funds at year-end.
- The company completed its IPO in May 2019. Outstanding preferred stock converted to common stock; the former term loan had been repaid in 2018, and the IPO triggered payment of a $675,000 loan success fee in 2019.
Outlook, commentary, risks and unusual items
- PRISM had enrolled approximately 45% of its target enrollment by the filing date. Enrollment was slower than expected because of competing trials and slower European site start-ups. Management expected a sample-size re-estimation in mid-2020; enrollment could rise from 240 to as many as 360, potentially delaying top-line data, which was then expected in the second half of 2020.
- The company planned an additional Phase 3 trial to support potential U.S. and European applications for prurigo nodularis. It also expected Phase 2 IPF cough data in the second half of 2020. These are forward-looking expectations, not reported outcomes.
- Prior evidence is mixed: the 2016 prurigo nodularis Phase 2 trial did not meet its primary endpoint. Certain favorable completer analyses were post hoc and not powered for statistical significance. In the uremic-pruritus Phase 2b/3 trial, the 108 mg arm met its primary endpoint, while the 54 mg arm did not; the company was not actively developing that indication.
- Management identified substantial clinical, regulatory, funding and commercialization uncertainty. COVID-19 had already caused disruptions at some European trial sites and could affect enrollment, monitoring, suppliers and trial timelines.
- Nalbuphine ER is opioid-related. Potential risks include nausea, dizziness, somnolence, psychiatric effects, respiratory or cardiac safety concerns, and possible FDA risk-management requirements or controlled-substance classification. Planned abuse-liability and cardiac-safety studies remained outstanding.
- The company relies on contract manufacturers and a single named supplier, Mallinckrodt, for nalbuphine drug substance; it had no long-term supply agreement guaranteeing quantities or pricing and had not qualified an alternate source. Commercial-scale manufacturing arrangements were not in place.
- Potential future obligations include Endo milestones and royalties, Rutgers milestone payments of up to approximately $330,500, and MentiNova milestone payments of up to approximately $1.188 million, plus potential royalties. The filing reports no material legal proceedings.
Most important facts for investors to verify
- PRISM enrollment, the sample-size re-estimation outcome, any trial delays, and whether the primary endpoint is met.
- Actual cash burn and financing needs relative to management’s runway estimate, particularly if trial enrollment or study size increases.
- Whether subsequent pivotal-trial requirements, safety studies, or regulatory feedback change the development timeline or cost.
- How clinical evidence compares with the failed prurigo nodularis Phase 2 primary endpoint, including the limitations of post hoc analyses.
- Whether supply arrangements, alternative drug-substance sources, and commercial manufacturing capacity are secured.